**Supplementary Table.**

**“A new, triglycyl peptide linker for antibody-drug conjugates (ADCs) with improved targeted killing of cancer cells”**

**Supplementary Table S1**: Amounts of catabolites generated upon treatment of cancer cells with CX and SMCC ADCs.

|  |  |
| --- | --- |
| Target, **Supplementary Table S1**: Amounts of catabolites generated upon treatment of cancer cells with CX and SMCC ADCs. *Cell line* *(antigen number per cell)* |  Catabolites, pmol/millioncells (1 day) *a*  |
| Cell |  Medium |  Total |  |  |
| CX SMCC |  CX SMCC |  CX SMCC |
| EGFR |
|  *HSC-2* *(106)* | 0.72 1.78  |  2.77 0.25 |  3.49 2.03 |
|  *A-431*  *(9.7*x*105)*  | 0.94 1.15 |  0.89 0.18 |  1.80 1.30 |  |  |
|  *HCC827* *(6.7*x*105)* | 1.06 1.10 |  1.66 0.88 |  2.70 2.00 |  |  |
| EpCAM |
|  *Calu-3* *(3.6*x*105)* |  0.83 0.71  |  0.37 0.09  |  1.20 0.80 |
|  *COLO 205* *(9.3*x*105)* |  0.77 1.03 |  2.40 1.60 |  3.17 2.63 |
|  *HT-29* *(5-7*x*105)*  | 0.91 1.02 |  0.67 0.38 |  1.60 1.40 |

*a*Cells were incubated with 2 g/mL (12 nM) ADC for ~2 h at 37 °C, then washed with medium to remove the unbound ADC, and further incubated in fresh medium for 1 day to allow processing. The catabolites in methanolic cell extract and medium were measured using maytansinoid-binding competition ELISA.